Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2019-08-06 Declaration of Voting R…
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (Code de commerce and Règlement Général de l'Autorité des Marchés Financiers - AMF) and provides a monthly update (as of July 31, 2019) detailing the total number of shares and voting rights. This type of regular disclosure concerning the capital structure and voting rights is most closely aligned with notifications regarding significant share ownership changes or capital structure updates. Since it is a monthly update on the total number of shares and voting rights, it fits best under Major Shareholding Notification (MRQ) or potentially Share Issue/Capital Change (SHA). However, the core purpose is reporting the current voting power structure, which is a key component of major shareholding disclosures, even if it's a routine monthly filing rather than a specific threshold breach. Given the options, MRQ (Major Shareholding Notification) is the most appropriate fit for routine capital structure/voting rights disclosure, although it is a French-specific filing type that often overlaps with general regulatory filings. Since it is a specific, recurring disclosure about the capital base, I will classify it as MRQ, as it relates directly to the composition of ownership/voting rights.
2019-08-06 French
Informations privilégiées / Autres communiqués
Share Issue/Capital Change Classification · 99% confidence The document is a press release dated July 25, 2019, announcing that NANOBIOTIX confirms its eligibility for the PEA-PME tax incentive scheme for the sixth consecutive year. This announcement relates to the company's status regarding investment eligibility criteria (market capitalization, employee count, revenue/balance sheet total) under French financial regulations (Code monétaire et financier). This type of announcement, which communicates a specific corporate status or regulatory compliance confirmation rather than detailed financial results (ER, IR), management changes (MANG), or shareholder voting (DVA), fits best under the general category for regulatory announcements or specific corporate updates that don't match other codes. Since it is a specific announcement about compliance/status rather than a major financing event (CAP) or a general regulatory filing fallback (RNS), I must check the definitions. It is not an AGM-R, 10-K, AR, MANG, CT, CAP, DVA, DLST, DIRS, ER, SR, XLSX, FS, CGR, IRAT, IR, IP, LTR, TAR, MRQ, MDA, NAV, DIV, PSI, DEF 14A, RPA, SHA, or POS. It is a specific corporate update that is not a standard financial report or insider transaction. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a specific, non-standard regulatory compliance confirmation press release that doesn't fit the other specific categories, although 'CAP' might be considered if the eligibility itself was a financing event, which it is not. It is a general regulatory/corporate status update.
2019-07-25 French
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 98% confidence The document is titled "Chiffres d'affaires du deuxième trimestre 2019" (Second Quarter 2019 Revenue) and presents unaudited financial results for Q2 2019, including a summary income statement and cash position as of June 30, 2019. It also mentions key operational milestones (CE mark for Hensify®) and financing activities. This content structure—a focused release of period-specific financial highlights—is characteristic of an Earnings Release (ER). It is not the comprehensive Annual Report (10-K) or the detailed Interim/Quarterly Report (IR), as it focuses on key figures and announcements rather than a full set of financial statements and MD&A. The document explicitly states the next financial release will be the 'Résultats semestriels' (Half-year results), confirming this is a shorter, periodic update. Q2 2019
2019-07-19 French
Inside Information / News release on accounts, results
Earnings Release Classification · 98% confidence The document is explicitly titled "NANOBIOTIX ANNOUNCES SECOND QUARTER 2019 REVENUE" and presents unaudited financial figures for Q2 2019, including revenue (€31.9K) and cash availability (€54.9M). It also mentions subsequent financing activities and organizational changes. This content structure—announcing key financial metrics for a specific interim period (Q2)—is characteristic of an Earnings Release (ER). It is not a comprehensive Annual Report (10-K) or a detailed Interim Report (IR), but rather the initial press release highlighting the results. The document also mentions the next financial press release date, confirming its nature as a periodic results announcement. Q2 2019
2019-07-19 English
Inside Information / Other news releases
Regulatory Filings Classification · 98% confidence The document is a press release dated July 9, 2019, announcing that Phase III Soft Tissue Sarcoma data for NBTXR3 has been published in *The Lancet Oncology*. It details the positive results (pCR, R0 rate) and includes quotes from key personnel. This is a communication to the market about a significant clinical/regulatory event (publication of trial results) and the subsequent regulatory/commercial implications (CE marking). It is not the full Annual Report (10-K), an Interim Report (IR), or a formal Audit Report (AR). Since it is an announcement of a major clinical/scientific milestone and the associated data publication, it fits best as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were a slide deck, but as a press release announcing publication, RNS is the most appropriate general category for significant, non-standardized corporate news, or potentially an Earnings Release (ER) if it were tied to a quarterly period, which it is not explicitly. Given the content is a news announcement about data publication and regulatory milestones, RNS (Regulatory Filings/General Announcement) is the best fit, as it is not a specific financial report type like 10-K or IR.
2019-07-09 English
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 98% confidence The document is a press release dated July 9, 2019, announcing that clinical trial data for the product NBTXR3 in Soft Tissue Sarcoma has been published in *The Lancet Oncology*. The text focuses on announcing the publication of scientific results, quoting key personnel (CMO, Principal Investigator), and summarizing the positive outcomes (pCR, R0 rates). This structure—announcing the release/publication of significant data or results—fits the definition of a Report Publication Announcement (RPA), which covers announcements regarding the timing, release, or publication of company reports, especially when the document itself is a summary press release pointing to the external publication (The Lancet Oncology) and providing a link to further details/the original announcement PDF. It is not the full Annual Report (10-K), a quarterly report (IR), or a transcript (CT). Since it explicitly announces the publication of data in a major journal, RPA is the most precise fit over the general fallback RNS.
2019-07-09 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.